192 related articles for article (PubMed ID: 24974778)
1. Treatment fractionation for stereotactic radiotherapy of lung tumours: a modelling study of the influence of chronic and acute hypoxia on tumour control probability.
Lindblom E; Antonovic L; Dasu A; Lax I; Wersäll P; Toma-Dasu I
Radiat Oncol; 2014 Jun; 9():149. PubMed ID: 24974778
[TBL] [Abstract][Full Text] [Related]
2. Optimal fractionation in radiotherapy for non-small cell lung cancer--a modelling approach.
Lindblom E; Dasu A; Toma-Dasu I
Acta Oncol; 2015; 54(9):1592-8. PubMed ID: 26217986
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia Induced by Vascular Damage at High Doses Could Compromise the Outcome of Radiotherapy.
Lindblom EK; Dasu A; Toma-Dasu I
Anticancer Res; 2019 May; 39(5):2337-2340. PubMed ID: 31092425
[TBL] [Abstract][Full Text] [Related]
4. Computed 88% TCP dose for SBRT of NSCLC from tumour hypoxia modelling.
Ruggieri R; Stavreva N; Naccarato S; Stavrev P
Phys Med Biol; 2013 Jul; 58(13):4611-20. PubMed ID: 23771131
[TBL] [Abstract][Full Text] [Related]
5. Impact of SBRT fractionation in hypoxia dose painting - Accounting for heterogeneous and dynamic tumor oxygenation.
Kjellsson Lindblom E; Ureba A; Dasu A; Wersäll P; Even AJG; van Elmpt W; Lambin P; Toma-Dasu I
Med Phys; 2019 May; 46(5):2512-2521. PubMed ID: 30924937
[TBL] [Abstract][Full Text] [Related]
6. Hypofractionation in non-small cell lung cancer (NSCLC): suggestions from modelling both acute and chronic hypoxia.
Ruggieri R
Phys Med Biol; 2004 Oct; 49(20):4811-23. PubMed ID: 15566177
[TBL] [Abstract][Full Text] [Related]
7. Optimal dose and fraction number in SBRT of lung tumours: A radiobiological analysis.
Ruggieri R; Stavrev P; Naccarato S; Stavreva N; Alongi F; Nahum AE
Phys Med; 2017 Dec; 44():188-195. PubMed ID: 28130055
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia dose painting in SBRT - the virtual clinical trial approach.
Schiavo F; Toma-Dasu I; Kjellsson Lindblom E
Acta Oncol; 2023 Oct; 62(10):1239-1245. PubMed ID: 37713263
[TBL] [Abstract][Full Text] [Related]
9. Calculating the individualized fraction regime in stereotactic body radiotherapy for non-small cell lung cancer based on uncomplicated tumor control probability function.
Lu JY; Lin PX; Huang BT
Radiat Oncol; 2019 Jun; 14(1):111. PubMed ID: 31221159
[TBL] [Abstract][Full Text] [Related]
10. Clinical oxygen enhancement ratio of tumors in carbon ion radiotherapy: the influence of local oxygenation changes.
Antonovic L; Lindblom E; Dasu A; Bassler N; Furusawa Y; Toma-Dasu I
J Radiat Res; 2014 Sep; 55(5):902-11. PubMed ID: 24728013
[TBL] [Abstract][Full Text] [Related]
11. Radiation-induced Vascular Damage and the Impact on the Treatment Outcome of Stereotactic Body Radiotherapy.
Lindblom EK; Hui S; Brooks J; Dasu A; Kujawski M; Toma-Dasu I
Anticancer Res; 2019 Jun; 39(6):2721-2727. PubMed ID: 31177107
[TBL] [Abstract][Full Text] [Related]
12. Optimal Radiation Therapy Fractionation Regimens for Early-Stage Non-Small Cell Lung Cancer.
Liu F; Ververs JD; Farris MK; Blackstock AW; Munley MT
Int J Radiat Oncol Biol Phys; 2024 Mar; 118(3):829-838. PubMed ID: 37734445
[TBL] [Abstract][Full Text] [Related]
13. A modified hypoxia-based TCP model to investigate the clinical outcome of stereotactic hypofractionated regimes for early stage non-small-cell lung cancer (NSCLC).
Strigari L; Benassi M; Sarnelli A; Polico R; D'Andrea M
Med Phys; 2012 Jul; 39(7):4502-14. PubMed ID: 22830782
[TBL] [Abstract][Full Text] [Related]
14. Histology-driven hypofractionated radiation therapy schemes for early-stage lung adenocarcinoma and squamous cell carcinoma.
Liu F; Farris MK; Ververs JD; Hughes RT; Munley MT
Radiother Oncol; 2024 Jun; 195():110257. PubMed ID: 38548113
[TBL] [Abstract][Full Text] [Related]
15. To fractionate or not to fractionate? That is the question for the radiosurgery of hypoxic tumors.
Toma-Dasu I; Sandström H; Barsoum P; Dasu A
J Neurosurg; 2014 Dec; 121 Suppl():110-5. PubMed ID: 25434944
[TBL] [Abstract][Full Text] [Related]
16. Modeling local control after hypofractionated stereotactic body radiation therapy for stage I non-small cell lung cancer: a report from the elekta collaborative lung research group.
Ohri N; Werner-Wasik M; Grills IS; Belderbos J; Hope A; Yan D; Kestin LL; Guckenberger M; Sonke JJ; Bissonnette JP; Xiao Y
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):e379-84. PubMed ID: 22999272
[TBL] [Abstract][Full Text] [Related]
17. Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer.
Guckenberger M; Klement RJ; Allgäuer M; Appold S; Dieckmann K; Ernst I; Ganswindt U; Holy R; Nestle U; Nevinny-Stickel M; Semrau S; Sterzing F; Wittig A; Andratschke N; Flentje M
Radiother Oncol; 2013 Oct; 109(1):13-20. PubMed ID: 24183066
[TBL] [Abstract][Full Text] [Related]
18. Tumor control probability in hypofractionated radiotherapy as a function of total and hypoxic tumor volumes.
Chvetsov AV; Hanin LG; Stewart RD; Zeng J; Rengan R; Lo SS
Phys Med Biol; 2021 Jun; 66(12):. PubMed ID: 34030139
[TBL] [Abstract][Full Text] [Related]
19. "Primer shot" fractionation with an early treatment break is theoretically superior to consecutive weekday fractionation schemes for early-stage non-small cell lung cancer.
Gouw ZAR; Jeong J; Rimner A; Lee NY; Jackson A; Fu A; Sonke JJ; Deasy JO
Radiother Oncol; 2024 Jan; 190():110006. PubMed ID: 37972733
[TBL] [Abstract][Full Text] [Related]
20. High brachytherapy doses can counteract hypoxia in cervical cancer-a modelling study.
Lindblom E; Dasu A; Beskow C; Toma-Dasu I
Phys Med Biol; 2017 Jan; 62(2):560-572. PubMed ID: 28033113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
